Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chromene derivative 3 is a synthetic small molecule belonging to the class of chromene-based compounds, specifically a 2H-chromene scaffold with substitution at the 3-position. It has been developed and studied as an antiproliferative agent with notable in vitro anticancer activity. In recent research, chromene derivative 3 demonstrated potent cytotoxic effects against several cancer cell lines, including breast cancer (MDA-MB-231 and MCF-7) and cervical cancer (HeLa), with IC₅₀ values of approximately 5.36 µM (MDA-MB-231), 7.82 µM (MCF-7), and 9.28 µM (HeLa)[8]. Mechanistically, this compound acts as a multi-targeted inhibitor affecting both Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) and BRAF V600E kinase pathways, which are key drivers in tumor angiogenesis and proliferation[8]. Molecular docking studies support its binding affinity for these targets. Chromene derivatives more broadly have also shown antimicrobial, antituberculosis, anticonvulsant, antidiabetic, anticholinesterase inhibitory activities[6], but "chromene derivative 3" specifically is characterized by its strong anticancer profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chromene derivative 3.